University of Illinois - Urbana/Champaign

Carle Cancer Center

Hematology Resource Page

Patient Resources

Protein C Deficiency

  • Home
  • Factor V Leiden
  • Antiphospholipid Syndrome
  • General Clotting Information
  • Prothrombin Gene Mutation
  • Hyperhomocysteinemia
  • Diseases from abnormal clotting
  • Antithrombin III deficiency
  • References
  • Protein C deficiency
  • Protein S deficiency

    Protein C deficiency is a genetic trait that predisposes one to the formation of venous clots. Protein C deficiency was first described in 1981.

    Mechanism of Action of Protein C Deficiency:
    A detailed description of the clotting process is found on the clotting information web page. The function of protein C is to inactivate factor Va and factor VIIIa (the 'a' denotes the active form). The first step in this process is the activation of thrombomodulin by thrombin. Subsequently, protein C combines with thrombomodulin in order to produce activated Protein C (see Figure 1). Activated protein C then combines with protein S on the surface of a platelet (platelets are the clotting cells that circulate in the blood and provide phospholipids to support that clotting process). Activated protein C can then degrade factor Va and factor VIIIa (see Figure 2).

    There are two classifications of protein C deficiency: type I and type II. Type I protein C deficiency results from an inadequate amount of protein C present (see Figure 3). The protein C that is present functions normally, but the amount of protein C present is insufficient to control the coagulation cascade. Type II protein C deficiency is characterized by defective protein C molecules (see Figure 4). The amount of protein C present is normal, but it is unable to interact normally with the other molecules involved in coagulation to perform its function. Numerous defects in the protein C molecule have been described that alter its interactions with thrombomodulin, phospholipids, factor Va and factor VIIIa as well as others.

    Epidemiology of Protein C Deficiency:
    Protein C deficiency is present in approximately 0.2% of the general population.

    Risks of Protein C Deficiency:
    The overall estimated incidence (annual occurrence) of deep venous thrombosis is 1 episode for every 1000 persons. This figure does not separate patients who had predisposing conditions from those who do not.

    For patients that are born with both of the copies of the protein C gene abnormal (called homozygous), the result is often a severe form of thrombosis called purpura fulminans. Purpura fulminans involves severe clotting throughout much of the body, ultimately causing death to the tissues. This is a life-threatening condition.

    At this time, the data available do not suggest any role between protein C deficiency and arterial thrombosis (stroke, heart attack).

    The role of protein C deficiency and venous thromboembolic disease is shown in the table below. The table shows the increase in risk compared with a patient without a known thrombophilic state. Relative risk is a numerical representation of the effects of a condition or treatment on an individual. If a condition or treatment has a relative risk of 1, patients with the condition have no additional risk or benefit from those without the condition. In the studies used below, a relative risk greater than 1 shows an increased risk. For the table below, a relative risk of 4 means that individuals with that condition are 4 times as likely as similar individuals without the same condition, to develop a venous thrombotic event. Despite the increased risk, it is important to remember that the relative risk is a statistical tool to help guide clinicians and scientists and that individual persons can have increased or decreased risks. Even with a very high relative risk, there is no guarantee that a venous thrombotic event will occur.

    Treatment of Protein C Deficiency:
    Treatment of a patient with protein C deficiency depends upon the individual patient's risk of thromboembolic disease. When a patient has a venous clot, regardless of what thrombophilic state(s) they may have, they will receive anticoagulation. This is accomplished by several different medications: 1) heparin, 2) warfarin and 3) low-molecular-weight heparins. These medications are generally continued for 3-6 months.

    Patients that have had multiple thromboembolic episodes or are at high risk of further episodes (for example, multiple deficiencies) may be considered for long-term oral anticoagulation (warfarin). Because studies have demonstrated an increased risk of recurrent venous thromboembolic disease in patients with protein C deficiency, long-term oral anticoagulation) is recommended. Long-term anticoagulation has risks associated with it (approximately a 3% chance per year of having a major hemorrhage, of which approximately 1/5 are fatal). Beginning long-term anticoagulation is influenced by the patient's overall risk of recurrent thrombosis balanced against the risks associated with long-term anticoagulation on an individual basis.

    In patients who are homozygous, the risk of death from thrombosis is imminent. As a result, treatment necessitates providing a source of protein C. This can be done through blood products such as fresh frozen plasma (FFP). In addition, a form of human protein C concentrates has become available in the United States. This has been used previously in Europe. At this time, there are no studies comparing the efficacy of FFP versus the protein C concentrates in severe protein C deficiency related thrombosis.

    Further Information:
    For further information on the other thrombophilic states, please refer to their respective pages. Brief information on the various medications that are discussed above and are regularly used to treat clotting disorders is discussed on the medication pages. A selection of the references used to compile this information is listed on the references page.

    Thrombophilic Status
    Relative Risk of Venous Thrombosis
    Normal 1
    Oral contraceptive (OCP) use 4
    Factor V Leiden, heterozygous 5 to 7
    Factor V Leiden, heterozygous + OCP 30 to 35
    Factor V Leiden, homozygous 80
    Factor V Leiden, homozygous + OCP ??? >100
    Prothrombin Gene Mutation, heterozygous 3
    Prothrombin Gene Mutation, homozygous ??? Also possible risk of arterial thrombosis
    Prothrombin Gene Mutation, heterozygous + OCP 16
    Protein C deficiency, heterozygous 7
    Protein C deficiency, homozygous Severe thrombosis at birth
    Protein S deficiency, heterozygous 6
    Protein S deficiency, homozygous Severe thrombosis at birth
    Antithrombin deficiency, heterozygous 5
    Antithrombin deficiency, homozygous Thought to be lethal prior to birth
    Hyperhomocysteinemia 2 to 4
    Hyperhomocysteinemia combined with Factor V Leiden, heterozygous 20
    *The terms heterozygous (hetero-different) and homozygous (homo-same) are terms used in genetics. The human genome contains to copies of the information. If the copies are the same, they are homozygous; if the copies are different, they are heterozygous. For example, take a protein called A. The normal genome would code for the protein as AA. This is homozygous for the normal protein. If there is a variation of the protein called a, there are two possible ways to get the a. The genome could be Aa, which is called heterozygous or the genome could be aa, which is called homozygous.